Compile Data Set for Download or QSAR
Report error Found 31 Enz. Inhib. hit(s) with all data for entry = 50015318
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585382(CHEMBL5085395)
Affinity DataKd:  6.20E+3nMAssay Description:Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissoc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585383(CHEMBL5072416)
Affinity DataKd:  560nMAssay Description:Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissoc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585384(CHEMBL5084171)
Affinity DataKd:  3.60E+4nMAssay Description:Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissoc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585381(CHEMBL5080840)
Affinity DataKd:  182nMAssay Description:Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissoc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585402(CHEMBL5081048)
Affinity DataIC50: 2nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585402(CHEMBL5081048)
Affinity DataIC50: 5nMAssay Description:Inhibition of human GDP-bound KRAS G12D mutant assessed as inhibition of SOS1-catalyzed nucleotide exchange by measuring KRAS G12D mutant/GTP/c-Raf1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585401(CHEMBL5083652)
Affinity DataIC50: 14nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585399(CHEMBL5087229)
Affinity DataIC50: 24nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585390(CHEMBL5089133)
Affinity DataIC50: 24nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585400(CHEMBL5085690)
Affinity DataIC50: 63nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585389(CHEMBL5093274)
Affinity DataIC50: 64nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585396(CHEMBL5091244)
Affinity DataIC50: 71nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585398(CHEMBL5070295)
Affinity DataIC50: 97nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585392(CHEMBL5074273)
Affinity DataIC50: 190nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585394(CHEMBL5091301)
Affinity DataIC50: 200nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585387(CHEMBL5091064)
Affinity DataIC50: 270nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585397(CHEMBL5094356)
Affinity DataIC50: 370nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585391(CHEMBL5084656)
Affinity DataIC50: 380nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585381(CHEMBL5080840)
Affinity DataIC50: 530nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585388(CHEMBL5087737)
Affinity DataIC50: 650nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585395(CHEMBL5091903)
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM573288(US11453683, Example 120 | US20230279025, Example 1...)
Affinity DataIC50: 1.30E+3nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585393(CHEMBL5093531)
Affinity DataIC50: 2.50E+3nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585386(CHEMBL5085544)
Affinity DataIC50: 3.00E+3nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585385(CHEMBL5080117)
Affinity DataIC50: 3.50E+3nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM573583(US11453683, Example 181 | US20230279025, Example 1...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585403(CHEMBL5073668)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585404(CHEMBL5079995 | US20230279025, Example 462)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585405(CHEMBL5082116)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50585406(CHEMBL5090577)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetGTPase KRas(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50503649(CHEMBL4476113)
Affinity DataKi:  2.00E+5nMAssay Description:Inhibition of KRAS G12C mutant (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed